Gossamer Bio Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Business Update

Author's Avatar
Mar 03, 2022

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the fourth quarter and year ended December 31, 2021 and provided a business update.